Biogen interim head of R&D Priya Singhal talked to the Pink Sheet about ramping up the Phase IV trial for Aduhelm, the CMS coverage determination and taking over R&D at a challenging time for the company.
Biogen, Inc. is pushing ahead with the Phase IV confirmatory trial for Aduhelm (aducanumab-avwa) and released some new details about the study on 27 January, even as the chance of securing widespread reimbursement for the Alzheimer’s drug in the near-term appears unlikely.
Priya Singhal, the company’s new interim head of R&D, talked to the Pink Sheet about taking over the leadership role...
Recent studies show that spaceflight can significantly weaken astronauts’ immune systems, making them more susceptible to infections and health complications during and after missions. Understanding these changes is crucial for ensuring the safety of future long-duration space travelers.
Revised recommendation is based on most recent data on circulating strains in US, where KP.3 is now dominant. Novavax sticks with plans targeting the JN.1 ‘parent strain.’
Pink Sheet reporter and editors discuss the US FDA’s changes to the COVID-19 vaccine indication and its revocation of the vaccine emergency use authorizations, as well as new vaccine coverage and reimbursement questions.
To make your document look professionally produced, Word provides header, footer, cover page, and text box designs that complement each other. For example, you can add a matching cover page, header, and sidebar. Click Insert and then choose the elements you want from the different galleries.
